CSF3 and vasculitis: While we initially considered a risk of G-CSF-associated aortitis recurrence if docetaxel had been continued without dose reduction, the successful completion of chemotherapy without vasculitis relapse was ultimately achieved by co-administering PSL with docetaxel and reducing the docetaxel dose to 55 mg/m2 in the second cycle.